X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Bioclinica Launches COVID-19 Clinical Endpoint Adjudication Solution

Content Team by Content Team
11th May 2020
in Clinical Trials, Drug Development, Press Statements
GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19

Bioclinica has introduced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica’s new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team, and a cutting-edge endpoint adjudication platform to help pharmaceutical and medical device researchers discern COVID-related adverse events from those not associated with COVID-19.

“For ongoing clinical trials that might be impacted by COVID-19, we recognize that time is of the essence. COVID-related maladies can significantly confound the safety analysis of ongoing clinical trials,” said Dan Gebow, senior vice president of research and development, Bioclinica. “As a company founded and led by scientists, we understand the importance of having the best research tools at our fingertips – especially when adapting to a rapidly changing landscape as we are experiencing during this pandemic.”

Bioclinica’s COVID-19 Clinical Adjudication Solution is designed to quickly evaluate a clinical trial protocol and charter to determine if novel COVID endpoint adjudication pathways should be added. Researchers can elect to utilize Bioclinica’s pre-programmed COVID Source Document collection system, COVID Adjudication Pathways, and expert adjudicators, or they can customize each component to best suit their trial.

Bioclinica’s expert physician adjudication network was formed in partnership with C. Michael Gibson, M.S., M.D. of Boston Clinical Research Institute (BCRI) and Harvard Medical School. The network consists of experienced adjudicators from Cardiology, Pulmonology, Neurology, Hepatology, Gastroenterology, and other specialties impacted by the deadly virus.

“The COVID-19 pandemic has given rise to a new specialist, the ‘Covidoligists’ who are adept at diagnosing and caring for a new constellation of inflammatory, infectious, and thrombotic complications affecting many organ systems,” said Dr. Gibson.

“We felt we were in a unique position to assist our fellow researchers, as our team can offer adjudication services and cloud-based software under-one-roof,” said Dr. Gebow. “COVID-19 adds significant risk for pharmaceutical and medical device clinical trials by confounding important safety endpoints. Our solution minimizes that risk by eliminating the need to patch together various endpoint adjudication services, expertise, and software from multiple disparate sources.”

Bioclinica’s COVID-19 Adjudication Solution can be used as a standalone solution for new research studies or as an add-on to ongoing studies. Moreover, as new trials launch that specifically focus on COVID-19 detection, treatment, and surveillance, Bioclinica’s COVID-19 Adjudication Solution efficiently facilitates adjudication of resulting adverse events.

Previous Post

Aptar Submits Application for EUA to the German Regulatory Agency BfArM for ActivShieldTM FFP2 Decontamination System

Next Post

Humanigen Initiates Phase III Lenzilumab Study in COVID-19

Related Posts

ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability
Manufacturing

ACHEMA 2022 addresses the industry’s key issues digitalisation and sustainability

14th June 2022
development of new antibiotics
Drug Development

EMA guidance supports development of new antibiotics

30th May 2022
Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
Conver to wp
Drug Development

AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

18th May 2022
Drug Imagent For Therapeutic Platform
Drug Development

Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

18th May 2022
Next Post
Savara clinial trial

Humanigen Initiates Phase III Lenzilumab Study in COVID-19

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In